Роль тиотропия бромида в базисной терапии хронической обструктивной болезни легких


С.Н. Авдеев

НИИ пульмонологии ФМБА России
Современный уровень развития клинической медицины дает возможность эффективно воздействовать на течение хронической обструктивной болезни легких (ХОБЛ). Особое место среди лекарственных средств, используемых в терапии стабильного периода ХОБЛ, занимают длительно действующие бронходилататоры (ДДБД), в частности тиотропия бромид, который относится к базисным препаратам для длительной поддерживающей терапии ХОБЛ. Тиотропий улучшает функциональные легочные показатели, симптомы, физическую работоспособность, качество жизни больных ХОБЛ, уменьшает число обострений заболевания.

Литература



  1. Global Initiative for Chronic Obstructive Lung Diseas (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. The 2009 report is available on www.goldcopd.com

  2. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007;370:741–50.

  3. Чучалин А.Г., Овчаренко С.И., Лещенко И.В., Белевский А.С. Определение, класси-фикация и диагностика ХОБЛ. В кн.: Клинические рекомендации. Хроническая обструктивная болезнь легких / Под ред. А.Г. Чучалина. М., 2007. С. 8–22.

  4. Celli BR, MacNee W. ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932–46.

  5. Panning CA, DeBisschop M. Tiotropium: an inhaled, long-acting anticholinergic drug for chronic obstructive pulmonary disease. Pharmacotherapy 2003;23:183–89.

  6. Tashkin DP. Long-acting anticholinergic use in chronic obstructive pulmonary disease: efficacy and safety. Curr Opin Pulm Med 2010;16:97–105.

  7. Donohue JF, van Noord JA, Bateman ED, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002;122:47–55.

  8. Celli B, Wallack RZ, Wang S, et al. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 2003;124:1743–48.

  9. Cazzola M, Matera MG. Emerging inhaled bronchodilators: an update. Eur Respir J 2009;34:757–69.

  10. Bauwens O, Ninane V, Van de Maele B, et al. 24-hour bronchodilator efficacy of single doses indacaterol in subjects with COPD: comparison with placebo and formoterol. Curr Med Res Opin 2009;25:463–70.

  11. Beier J, Beeh KM, Brookman L, et al. Bronchodilator effects of indacaterol and formoterol in patients with COPD. Pulm Pharmacol Ther 2009;22(6):492–96.

  12. Fogarty C, Worth H, Hebert J, et al. Sustained 24-h bronchodilation with indacaterol once-daily in COPD: a 26-week efficacy and safety study. Am J Respir Crit Care Med 2009;179: A4547.

  13. Magnussen H, Paggiaro P, Jack D, et al. Bronchodilatador treatment with indacaterol once-daily vs formoterol twice – daily in COPD: a 52-week study. Am J Respir Crit Care Med 2009;179:A6184.

  14. Nonikov V, Verkindre C, Jack D, et al. Indacaterol once-daily reduces days of poor control in COPD over 52 weeks of treatment. Am J Respir Crit Care Med 2009;179 A6190.

  15. Magnussen H, Paggiaro P, Jack D, et al. Indacaterol once-daily improves health-related quality of life in COPD patients: a 52-week study versus placebo and formoterol. Eur Respir J 2009;53s:P2019.

  16. Buhl R, Pieters W, Jack D, et al. Indacaterol once-daily improves dyspnoea and BODE index in COPD patients: a 52- week study versus twice-daily formoterol. Eur Respir J 2009;53s:P2026.

  17. Buhl R, Pieters W, Jack D, et al. Indacaterol once-daily reduces COPD exacerbations over 52 weeks of treatment. Am J Respir Crit Care Med 2009;179:A6185.

  18. Worth H, Kleerup E, Iqbal A, et al. Safety and tolerability of indacaterol once-daily in COPD patients versus placebo and tiotropium: a 26-week study. Eur Respir J 2009;53s:P2030.

  19. Chung F, Kornmann O, Jack D, et al. Safety and tolerability of indacaterol over 52 weeks of treatment in COPD. Eur Respir J 2009;53s:E4359.

  20. Fletcher CM. Elmes PC, Wood CH. The significance of respiratory symptoms and the diagnosis of chromic bronchitis in a working population. BMJ 1959;1:257–66.

  21. Kohansal R, Martinez-Camblor P, Agust A, et al. The Natural History of Chronic Airflow Obstruction Revisited: An Analysis of the Framingham Offspring Cohort Am J Respir Crit Care Med 2009;180:3–10.

  22. Decramer M, Celli B, Tashkin DP, et al. Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the Uplift trial. COPD 2004;1 303–12.

  23. Scanlon PD, Connett JE, Waller LA, et al. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease: the Lung Health Study. Am J Respir Crit Care Med 2000;161 381–90.

  24. Anthonisen NR, Skeans MA,Wise RA, et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005;142: 233–39.

  25. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543–54.

  26. Vincken W, van Noord JA, Greefhorst APM, et al. Improved health outcomes in patients with COPD during 1 yr’s treatment with tiotropium. Eur Respir J 2002;19:209–16.

  27. Anzueto A, Tashkin D, Menjoge S, Kesten S. One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. Pulm Pharmacol Ther 2005;18:75–81.

  28. Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med 1999;340:1948–53.

  29. Vestbo J, Sorensen T, Lange P, et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999;353: 1819–23.

  30. The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000;343:1902–909.

  31. Burge PS, Calverley PMA, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320:1297–303.

  32. Decramer M, Rutten-van Molken M, Dekhuijzen PN, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomized placebo-controlled trial. Lancet 2005;365:1552–60.

  33. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of COPD: a randomised controlled trial. Lancet 2003;361(9356):449–56.

  34. Decramer M, Celli B, Kesten S, et al., for the UPLIFT investigators. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecied subgroup analysis of a randomised controlled trial. Lancet 2009;374:1171–78.

  35. Troosters T, Celli B, Lystig T, et al. Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial. Eur Respir J 2010;36:65–73.

  36. Morice AH, Celli B, Kesten S, et al. COPD in young patients: A pre-specified analysis of the four-year trial of tiotropium (UPLIFT). Respir Med 2010;104:1659–67.

  37. Murray CJL, Lopez AD. Mortality by cause for eight regions of the world: global burden of disease study. Lancet 1997;349: 1269–76.

  38. Mannino DM, Homa DM, Akinbami LJ, et al. Chronic obstructive pulmonary disease surveillance – United States, 1971–2000. MMWR Surveill Summ 2002;51:1–16.

  39. World Health Organization. Global initiative for chronic obstructive lung disease. Geneva (Switzerland): World Health Organization; 2002.

  40. Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1981;i:681–86.

  41. Nocturnal Oxygen Therapy Trial Group: Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med 1980;93:391–98.

  42. Anthonisen NR, Skeans MA,Wise RA, et al. The effects of a smoking cessation intervention on 14,5-year mortality: a randomized clinical trial. Ann Intern Med 2005;142:233–39.

  43. National Emphysema Treatment Trial Research Group. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003;348:2059–73.

  44. Lightowler JV, Wedzicha JA, Elliott MW, Ram FS. Non-invasive positive pressure ventilation to treat respiratory failure resulting from exacerbations of chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis. BMJ 2003;326:185–89.

  45. Salpeter SR, Buckley NS, Salpeter EE. Meta-analysis: Anticholinergics, but not b-agonists, Reduce Severe Exacerbations and Respiratory Mortality in COPD. J Gen Intern Med 2006;21:1011–19.

  46. De Luise C, Lanes SF, Jacobsen J, et al. Cardiovascular and respiratory hospitalizations and mortality among users of tiotropium in Denmark. Eur J Epidemiol 2007; 22:267–72.

  47. Hansell AL, Walk JA, Soriano JB. What do chronic obstructive pulmonary disease patients die from? A multiple cause coding analysis. Eur Respir J 2003;22:809–14.

  48. Camilli AE, Robbins DR, Lebowitz MD. Death certificate reporting of confirmed airways obstructive disease. Am J Epidemiol 1991; 133:795–800.

  49. Engstrom G, Wollmer P, Hedblad B, et al. Occurrence and prognostic significance of ventricular arrhythmia is related to pulmonary function: a study from “men born in 1914”, Malmo, Sweden. Circulation 2001;103:3086–91.

  50. Huiart L, Ernst P, Suissa S. Cardiovascular morbidity and mortality in COPD. Chest 2005; 128:2640–46.

  51. Viegas CA, Ferrer A, Montserrat JM. Ventilation-perfusion response after fenoterol in hypoxemic patients with stable COPD. Chest 1996;110:71–7.

  52. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease. A systematic review and meta-analysis. JAMA 2008;300:1439–50.

  53. Celli B, Decramer M, Leimer I, et al. Cardiovascular safety of tiotropium in patients with COPD. Chest 2010;137;20–30.

  54. Reilly JJ. COPD and Declining FEV1 – Time to Divide and Conquer? N Engl J Med 2008;359:1616–18.

  55. Burrows B, Fletcher CM, Heard BE, et al. The emphysematous and bronchial types of chronic airways obstruction. A clinicopathological study of patients in London and Chicago. Lancet 1966;87: 830–35.

  56. Garcia-Aymerich J, Agusti А, Barberа JA, et al. Phenotypic Heterogeneity of Chronic Obstructive Pulmonary Disease. Arch Bronconeumol 2009;45:133–42.

  57. Han MK, Agusti A, Calverley PM, et al. COPD phenotypes: The future of COPD. Am J Respir Crit Care Med 2010;182:598–604.

  58. Lee J-H, Lee YK, Kim E-K, et al. Responses to inhaled long-acting beta-agonist and corticosteroid according to COPD subtype. Respir Med 2010;104:542–49.

  59. Gelb AF, Taylor CF, Cassino C, et al. Tiotropium induced bronchodilation and protection from dynamic hyperinflation is independent of extent of emphysema in COPD. Pulm Pharmacol Ther 2009; 22:237–42.

  60. Tashkin DP, Celli B, Kesten S, et al. Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial. Eur Respir J 2010; 35:287–94.

  61. Tashkin DP, Celli B, Kesten S, et al. Effect of tiotropium in men and women with COPD: Results of the 4-year UPLIFT trial. Respir Med 2010;104:1495–504.


Похожие статьи


Бионика Медиа